The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26

This publication has 26 references indexed in Scilit:

• Bombesin Antagonist–Based Radioligands for Translational Nuclear Imaging of Gastrin-Releasing Peptide Receptor–Positive Tumors
  Journal of Nuclear Medicine, 2011
• Novel ⁶⁴Cu- and ⁶⁸Ga-Labeled RGD Conjugates Show Improved PET Imaging of α_νβ₃ Integrin Expression and Facile Radiosynthesis
  Journal of Nuclear Medicine, 2011
• PET of Somatostatin Receptor–Positive Tumors Using ⁶⁴Cu- and ⁶⁸Ga-Somatostatin Antagonists: The Chelate Makes the Difference
  Journal of Nuclear Medicine, 2011
• Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
  Chemical Reviews, 2010
• Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog
  European Journal of Nuclear Medicine and Molecular Imaging, 2010
• Impact of bifunctional chelators on biological properties of 111In-labeled cyclic peptide RGD dimers
  Amino Acids, 2010
• Preparation and Biological Evaluation of ⁶⁴Cu-CB-TE2A-sst₂-ANT, a Somatostatin Antagonist for PET Imaging of Somatostatin Receptor–Positive Tumors
  Journal of Nuclear Medicine, 2008
• Radiolabeled somatostatin receptor antagonists are preferable to agonists forin vivopeptide receptor targeting of tumors
  Proceedings of the National Academy of Sciences, 2006
• Targeting prostate cancer with radiolabelled bombesins
  Cancer Imaging, 2006
• Gastrin-Releasing Peptide Receptors in Non-Neoplastic and Neoplastic Human Breast
  The American Journal of Pathology, 1999